NEUROCRINE BIOSCIENCES INC Receivables, Net, Current
NEUROCRINE BIOSCIENCES INC (NBIX) had Receivables, Net, Current of $439.30 million as of 2023-12-31, per its 10-K filed 2024-02-09.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:ReceivablesNetCurrent · last filed 2024-02-09
- 2023-12-31: Receivables, Net, Current $439.30M.
- 2022-12-31: Receivables, Net, Current $350.00M.
- 2016-03-31: Receivables, Net, Current $15.08M.
- 2015-03-31: Receivables, Net, Current $30.03M.
| Period end | Receivables, Net, Current | Receivables, Net, Current as first filed |
|---|---|---|
| 2023-12-31 | $439.30M 10-K · filed 2024-02-09 | |
| 2022-12-31 | $350.00M 10-K · filed 2024-02-09 | |
| 2016-03-31 | $15.08M 10-Q · filed 2016-05-05 | |
| 2015-03-31 | $30.03M 10-Q · filed 2015-04-30 | |
| 2014-06-30 | $2.92M 10-Q · filed 2014-08-06 | |
| 2014-03-31 | $1.87M 10-Q · filed 2014-05-01 | |
| 2013-12-31 | $2.72M 10-Q · filed 2014-08-06 | $23.00K 10-K · filed 2014-02-11 |
| 2013-09-30 | $75.00K 10-Q · filed 2013-10-29 | |
| 2013-06-30 | $38.00K 10-Q · filed 2013-07-26 | |
| 2013-03-31 | $8.00K 10-Q · filed 2013-05-02 | |
| 2012-12-31 | $14.09M 10-K · filed 2014-02-11 | |
| 2012-09-30 | $1.37M 10-Q · filed 2012-10-31 | |
| 2012-06-30 | $1.54M 10-Q · filed 2012-07-31 | |
| 2012-03-31 | $1.81M 10-Q · filed 2012-05-02 | |
| 2011-12-31 | $1.90M 10-K · filed 2013-02-08 | |
| 2011-09-30 | $22.40M 10-Q · filed 2011-10-31 | |
| 2011-06-30 | $2.91M 10-Q · filed 2011-07-29 | |
| 2010-12-31 | $4.47M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |